Yahoo Web Search

  1. Ads
    related to ELI LILLY AND COMPANY
  1. This week the FDA granted quite a few approvals for line extensions of Lilly LLY, Pfizer PFE and Roche RHHBY/AbbVie’s ABBV cancer drugs. In other news, Bayer BAYRY was fined $2 ...

  2. Pharma ETFs Down Despite Solid Q1 Results

    Zacks via Yahoo FinanceMay 09 14:05 PM

    Earnings per share came in at $2.10, ahead of the Zacks Consensus Estimate by 7 cents and also 1.9% higher than the year-ago quarter. Revenues inched up 3.9% year over year to $20.02 ...

  3. Eli Lilly and Company LLY announced that a phase II study evaluating its pipeline candidate mirikizumab in patients with moderately-to-severely active Crohn's disease ...

  4. Allergan plc’s AGN first-quarter adjusted earnings came in at $3.79 per share, which beat the Zacks Consensus Estimate of $3.55 and came ahead of the guidance of $3.40 and $3.60 ...

  5. While the primary endpoints were the proportion of patients who achieved clear or almost clear skin improvement and the proportion who achieved at least a 75% or greater change in their ...

  6. Aduro has a collaboration and license agreement with Novartis NVS for developing its lead STING Activator candidate, ADU-S100. In February this year, Aduro dosed the first patient in ...

  7. TV pitches for prescription drugs will have to include price

    Associated Press via Yahoo FinanceMay 08 23:44 PM

    Health and Human Services Secretary Alex Azar said Wednesday the Trump administration has finalized regulations requiring drug companies to disclose list prices of medications costing ...

  8. 111, Inc. (YI) Q1 2019 Earnings Call Transcript

    Motley Fool via Yahoo FinanceMay 16 18:51 PM

    Ladies and gentlemen, thank you for standing by and welcome to the first quarter 2019 earnings conference call. Among other things, this outlook in quotations for management in ...

  9. Eli Lilly & Company LLY announced that the lower priced version of its popular insulin, Humalog is now available for order in pharmacies across the United States. Lilly ...

  10. Why Are Investors Passing on Teva Pharmaceutical Industries?

    Motley Fool via Yahoo FinanceMay 05 11:00 AM

    Teva Pharmaceutial Industries (NYSE: TEVA) is a dirt-cheap pharma stock. Why are investors passing on Teva even at these bargain-bin levels? Teva's $40.5 billion acquisition of Allergan's (NYSE ...

  1. Ads
    related to ELI LILLY AND COMPANY